live biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)

Class

live biotherapeutic (topical ammonia-oxidizing bacterium, AOBiome/B244)

Pathway

oxidizes skin ammonia to nitric oxide (immunomodulatory byproduct); suppresses Th2 immune polarization via IL-10, dampening dendritic-cell-driven Th2 activation

This mechanism involves a live biotherapeutic — a therapy made of living bacteria rather than a purified drug molecule — applied to the skin. Nitrosomonas eutropha is an ammonia-oxidizing bacterium that naturally lived on human skin before modern hygiene practices reduced such colonization. It metabolizes ammonia found in sweat, converting it into nitrite and nitric oxide, a small signaling molecule involved in blood vessel regulation, antimicrobial defense, and immune balance. The therapeutic rationale is that restoring these bacteria to the skin surface may re-establish a natural nitric oxide supply and, through it, recalibrate local immune signaling. Specifically, byproducts of this bacterial metabolism appear to promote interleukin-10, a regulatory cytokine that restrains dendritic cells, the immune cells responsible for steering T lymphocytes toward a Th2 (T helper type 2) pattern of response. Th2 polarization drives the itching, inflammation, and barrier breakdown seen in allergic and atopic skin conditions. By dampening this polarization at its dendritic-cell origin, the mechanism aims to reduce Th2-driven inflammation. This approach is broadly relevant to atopic dermatitis, other allergic or inflammatory skin diseases, and general questions about how the skin's resident microbial community shapes cutaneous immune tone.